178 related articles for article (PubMed ID: 19199318)
1. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells.
Kim TH; Lee SY; Rho JH; Jeong NY; Soung YH; Jo WS; Kang DY; Kim SH; Yoo YH
Mol Cancer Res; 2009 Oct; 7(10):1645-54. PubMed ID: 19825993
[TBL] [Abstract][Full Text] [Related]
3. Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system.
Nagayama Y; Nishihara E; Namba H; Yokoi H; Hasegawa M; Mizuguchi H; Hayakawa T; Hamada H; Yamashita S; Niwa M
Cancer Gene Ther; 2001 Jan; 8(1):36-44. PubMed ID: 11219492
[TBL] [Abstract][Full Text] [Related]
4. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
Lin CI; Whang EE; Abramson MA; Donner DB; Bertagnolli MM; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2009 Feb; 379(2):626-31. PubMed ID: 19124005
[TBL] [Abstract][Full Text] [Related]
7. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function.
Céraline J; Deplanque G; Noël F; Natarajan-Amé S; Bergerat JP; Klein-Soyer C
Cancer Chemother Pharmacol; 2003 Jan; 51(1):91-5. PubMed ID: 12497212
[TBL] [Abstract][Full Text] [Related]
9. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
10. Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.
Takano T; Ito Y; Matsuzuka F; Miya A; Kobayashi K; Yoshida H; Miyauchi A
Oncol Rep; 2007 Sep; 18(3):715-20. PubMed ID: 17671725
[TBL] [Abstract][Full Text] [Related]
11. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.
Kehlen A; Lendeckel U; Dralle H; Langner J; Hoang-Vu C
Cancer Res; 2003 Dec; 63(23):8500-6. PubMed ID: 14679016
[TBL] [Abstract][Full Text] [Related]
12. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas.
Kim YW; Do IG; Park YK
Pathol Res Pract; 2006; 202(11):759-65. PubMed ID: 17029809
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.
Asakawa H; Kobayashi T; Komoike Y; Maruyama H; Nakano Y; Tamaki Y; Matsuzawa Y; Monden M
Anticancer Res; 1997; 17(4A):2757-62. PubMed ID: 9252711
[TBL] [Abstract][Full Text] [Related]
14. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
Barzon L; Gnatta E; Castagliuolo I; Trevisan M; Moretti F; Pontecorvi A; Boscaro M; Palù G
Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
[TBL] [Abstract][Full Text] [Related]
15. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.
Lavra L; Rinaldo C; Ulivieri A; Luciani E; Fidanza P; Giacomelli L; Bellotti C; Ricci A; Trovato M; Soddu S; Bartolazzi A; Sciacchitano S
PLoS One; 2011; 6(6):e20665. PubMed ID: 21698151
[TBL] [Abstract][Full Text] [Related]
16. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.
Hanazono K; Natsugoe S; Stein HJ; Aikou T; Hoefler H; Siewert JR
Oncol Rep; 2006 Apr; 15(4):821-4. PubMed ID: 16525665
[TBL] [Abstract][Full Text] [Related]
17. Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells.
Zacal N; Espiritu M; Singh G; Rainbow AJ
Biochem Biophys Res Commun; 2005 Jun; 331(2):648-57. PubMed ID: 15850808
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
[TBL] [Abstract][Full Text] [Related]
19. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
20. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
